Due to the efficacy of the glucagon-like peptide 1 receptor agonist (GLP-1RA) class of pharmaceuticals in controlling T2DM, obesity, and related comorbidities, GLP1-RA might also reduce the risk for ORC. The gene discussed is GLP1R; the disease is obesity disorder.